Resultados de Búsqueda

NICE

NICE

Standard care for advanced or unresectable hepatocellular carcinoma is either sorafenib or lenvatinib for people who have not had previous systemic treatment. Atezolizumab plus bevacizumab is a potential new treatment option. Clinical trial evidence shows that people with Child-Pugh grade A liver impairment and an ECOG performance status of 0 or 1 who have atezolizumab plus bevacizumab live longer and have longer before their disease progresses than people who have sorafenib. Results of an ...

NICE

NICE

Liraglutide is recommended as an option for managing overweight and obesity alongside a reduced-calorie diet and increased physical activity in adults, only if they have a body mass index (BMI) of at least 35 kg/m2 (or at least 32.5 kg/m2 for members of minority ethnic groups known to be at equivalent risk of the consequences of obesity at a lower BMI than the white population) and they have non-diabetic hyperglycaemia (defined as a haemoglobin A1c level of 42 mmol/mol to 47 mmol/mol [6.0% to ...

NICE

NICE

People with untreated CLL are offered different treatments depending on whether they are likely to tolerate chemo-immunotherapy, and whether they have certain genetic abnormalities (such as a 17p deletion or TP53 mutation). In people with a 17p deletion or TP53 mutation, CLL does not usually respond well to standard chemo-immunotherapy, and ibrutinib is usually used. In people without a 17p deletion or TP53 mutation, FCR or BR are the most common chemo-immunotherapies used. If FCR or BR is ...

NICE

NICE

Migraine is a type of headache that can occur with symptoms such as nausea, vomiting, or sensitivity to light and sound. In many people, a throbbing pain is felt only on one side of the head. The evidence for administering galcanezumab in migraine (with the conditions set forth) comes from a clinical trial. Treatment options for preventing episodic or chronic migraine include beta-blockers, antidepressants and anticonvulsant drugs. If episodic migraine does not respond to at least 3 oral ...

NICE

NICE

In some people who have secondary progressive multiple sclerosis, a progressive one develops later in the course of the disease, often with overlapping relapses and without defined periods of remission. Between 30 and 50% of patients who are in the relapsing-remitting form of multiple sclerosis develop the secondary progressive form. The recommendation to administer siponimod in this type of multiple sclerosis comes from a clinical trial. Interferon beta-1b is the only disease-modifying ...